Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Choreo LLC

Choreo LLC raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 2.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 7,703 shares of the medical instruments supplier’s stock after acquiring an additional 170 shares during the period. Choreo LLC’s holdings in Becton, Dickinson and Company were worth $1,752,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC grew its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after buying an additional 877 shares during the period. E. Ohman J or Asset Management AB grew its stake in shares of Becton, Dickinson and Company by 13.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock valued at $39,951,000 after buying an additional 20,859 shares during the period. Arete Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company during the 3rd quarter valued at $767,000. Busey Bank grew its stake in shares of Becton, Dickinson and Company by 3.8% during the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after buying an additional 2,399 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after buying an additional 1,317,723 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BDX has been the subject of several research reports. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler boosted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $283.00.

Becton, Dickinson and Company Stock Up 1.3 %

Shares of Becton, Dickinson and Company stock opened at $230.22 on Friday. The company has a fifty day moving average price of $231.90 and a 200 day moving average price of $234.05. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $251.99. The stock has a market cap of $66.77 billion, a price-to-earnings ratio of 38.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. Equities research analysts forecast that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In other news, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the sale, the executive vice president now owns 5,741 shares in the company, valued at approximately $1,377,840. This represents a 8.01 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Roland Goette sold 638 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the sale, the executive vice president now owns 14,217 shares in the company, valued at approximately $3,113,949.51. This trade represents a 4.29 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock worth $2,210,716 in the last quarter. 0.36% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.